Liquidia adds over 30% on United Thera. settlement; BTIG upgrades
Liquidia shares surged over 30%, driven by a settlement agreement in its litigation with United Therapeutics and an upgrade from BTIG.
Consider entry based on the litigation settlement news and the sharp surge occurring from an extreme oversold condition; however, since the moving averages are not yet aligned, strict volatility management is required between the resistance level of $74.74 and the support level of $22.31.
Amid the rebound driven by the extreme oversold condition with an RSI of 18.3 and the favorable news of the litigation settlement, considering the unaligned moving averages, I will take profit when the price reaches the resistance level of $74.74, and cut losses if the risk increases by breaking below the support level of $22.31 to the downside.
At the time of entry, the RSI (14) stood at 18.3, indicating an extreme oversold condition. Moving averages were in a non-bullish alignment, trading volume was 0.84 times the 20-day average, and the 7-day volatility (rate of change) recorded -6.4%.
Past similar cases include the case on October 22, 2026, which shares the keyword 'Liquidia' (return: 44.9%, news: Biggest stock movers Wednesday: DELL, LQDA, ENVX and more), the case on October 29, 2026 (return: 36.7%, news: Liquidia adds over 30% on United Thera. settlement; BTIG upgrades), and the case on October 15, 2026 (return: 26.6%, news: Liquidia rockets 42% as $380.7M deal ends United Therapeutics legal battle).
Although the predicted return was set conservatively at 6.5%, the actual result recorded a high return of 36.7%, receiving an OVERHIT rating. We can review how, despite the technical burden of unaligned moving averages, market buying pressure flowed in much stronger than expected, driven by the convergence of an extreme oversold zone with an RSI of 18.3 and a strong positive catalyst in the form of a litigation settlement with United Therapeutics.
Through this trade, we confirmed that the major catalyst that emerged from the extreme oversold phase can propel the stock price into a rapid surge, extending beyond a simple technical rebound. Going forward, should similar overselling and catalyst occur simultaneously, we will adopt a strategy of flexibly adjusting take-profit thresholds while maintaining conservative targets, with consideration given to momentum strength.